Onconaut Secures a Fast-Track STTR Grant from NIH/NCI

Onconaut Therapeutics, a privately-held therapeutics company and prior Innosphere client company, has received $2.5M in funding through a Fast-Track Small Business Technology Transfer (STTR) grant from the National Institute of Health, National Cancer Institute (NCI) for Onconaut to develop small molecule drug inhibitor targeting Chromodomain Helicase DNA binding protein (CHD1L), a novel oncogenic target for metastatic colorectal cancer and other cancers. The grant will allow Onconaut to rapidly develop a lead compound suitable for preclinical IND studies as a single agent and in combination with FOLFIRI.